Zilong Hao1, Yiping Chen2,3, Neil Wright3, Haiqiang Qin4, Iain Turnbull3, Yu Guo5, Christiana Kartsonaki2,3, Sam Sansome3, Canqing Yu6, Qijun Gu7, Jianming Hu8, Jun Lv6, Liming Li6, Ming Liu1, Yongjun Wang4, Robert Clarke3, Zhengming Chen3. 1. Center of Cerebrovascular Disease, Department of Neurology, West China Hospital, Sichuan University, Chengdu, China. 2. Medical Research Council Population Health Research Unit, (PHRU), Nuffield Department of Population Health, University of Oxford, Oxford, UK. 3. Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK. 4. China National Clinical Research Centre for Neurological Disease; Beijing Institute for Brain Disorders; Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease; Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 5. Chinese Academy of Medical Sciences, Dong Cheng District, Beijing, China. 6. Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China. 7. Tongxiang CDC, Tongxiang, Zhejiang, China. 8. Shimen Town Health Center, Tongxiang, Zhejiang, China.
Abstract
BACKGROUND: Widespread use of brain imaging in China has resulted in an increased prevalence of silent lacunar infarct (LACI) in addition to symptomatic LACI, but their clinical relevance is not fully understood. METHODS: We compared the 5-year risks of recurrent stroke and all-cause mortality for silent LACI vs symptomatic LACI in a prospective study of 489,597 Chinese adults with no history of stroke or ischemic heart disease at baseline. Data on recurrent stroke and all-cause mortality were obtained by linkage with local stroke and mortality registries and health insurance records for all hospital admissions. FINDINGS: Among 12,150 cases with an adjudicated diagnosis of first-ever LACI, 4,134 (34%) had silent LACI and 8,016 (66%) had symptomatic LACI. All cases had brain imaging, but only 33% of silent LACI and 40% of symptomatic LACI cases had brain magnetic resonance imaging (MRI). The standardized event rates for silent LACI were 2-fold greater in urban than rural areas, but the ratios of silent LACI vs symptomatic LACI were similar in all areas. Cases with silent LACI vs symptomatic LACI had comparable 5-year risks of recurrent stroke (38% vs 43%) and all-cause mortality (11% vs 14%), respectively. For both silent and symptomatic LACI cases, most cases of recurrent stroke had non-LACI (70% vs 72%). While the relative risks of recurrent stroke did not differ by age, sex and area, the absolute risks of all-cause mortality varied by sex, age and area. INTERPRETATION: The prognosis of cases with silent LACI was comparable with symptomatic LACI, and the results highlight the need for further randomized trials assessing the efficacy and safety of established treatments for ischemic stroke in cases with silent LACI. FUNDING: Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904) and National Natural Science Foundation of China (91843302); UK Medical Research Council (MC_UU_00017/1,MC_UU_12026/2 MC_U137686851), Cancer Research UK (C16077/A29186; C500/A16896) and British Heart Foundation (CH/1996001/9454). ZH was supported West China Hospital, Sichuan University (ZYGD18009 and 2016YFC1300505) for a visiting scholarship to the University of Oxford, UK, during 2018-19.
BACKGROUND: Widespread use of brain imaging in China has resulted in an increased prevalence of silent lacunar infarct (LACI) in addition to symptomatic LACI, but their clinical relevance is not fully understood. METHODS: We compared the 5-year risks of recurrent stroke and all-cause mortality for silent LACI vs symptomatic LACI in a prospective study of 489,597 Chinese adults with no history of stroke or ischemic heart disease at baseline. Data on recurrent stroke and all-cause mortality were obtained by linkage with local stroke and mortality registries and health insurance records for all hospital admissions. FINDINGS: Among 12,150 cases with an adjudicated diagnosis of first-ever LACI, 4,134 (34%) had silent LACI and 8,016 (66%) had symptomatic LACI. All cases had brain imaging, but only 33% of silent LACI and 40% of symptomatic LACI cases had brain magnetic resonance imaging (MRI). The standardized event rates for silent LACI were 2-fold greater in urban than rural areas, but the ratios of silent LACI vs symptomatic LACI were similar in all areas. Cases with silent LACI vs symptomatic LACI had comparable 5-year risks of recurrent stroke (38% vs 43%) and all-cause mortality (11% vs 14%), respectively. For both silent and symptomatic LACI cases, most cases of recurrent stroke had non-LACI (70% vs 72%). While the relative risks of recurrent stroke did not differ by age, sex and area, the absolute risks of all-cause mortality varied by sex, age and area. INTERPRETATION: The prognosis of cases with silent LACI was comparable with symptomatic LACI, and the results highlight the need for further randomized trials assessing the efficacy and safety of established treatments for ischemic stroke in cases with silent LACI. FUNDING: Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z) and National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904) and National Natural Science Foundation of China (91843302); UK Medical Research Council (MC_UU_00017/1,MC_UU_12026/2 MC_U137686851), Cancer Research UK (C16077/A29186; C500/A16896) and British Heart Foundation (CH/1996001/9454). ZH was supported West China Hospital, Sichuan University (ZYGD18009 and 2016YFC1300505) for a visiting scholarship to the University of Oxford, UK, during 2018-19.
Authors: Daniel Bos; Frank J Wolters; Sirwan K L Darweesh; Meike W Vernooij; Frank de Wolf; M Arfan Ikram; Albert Hofman Journal: Alzheimers Dement Date: 2018-05-21 Impact factor: 21.566
Authors: Mariëlle M F Poels; Ewout W Steyerberg; Renske G Wieberdink; Albert Hofman; Peter J Koudstaal; M Arfan Ikram; Monique M B Breteler Journal: J Neurol Neurosurg Psychiatry Date: 2012-08-23 Impact factor: 10.154
Authors: Pierre Amarenco; Philippa C Lavallée; Linsay Monteiro Tavares; Julien Labreuche; Gregory W Albers; Halim Abboud; Sabrina Anticoli; Heinrich Audebert; Natan M Bornstein; Louis R Caplan; Manuel Correia; Geoffrey A Donnan; José M Ferro; Fernando Gongora-Rivera; Wolfgang Heide; Michael G Hennerici; Peter J Kelly; Michal Král; Hsiu-Fen Lin; Carlos Molina; Jong Moo Park; Francisco Purroy; Peter M Rothwell; Tomas Segura; David Školoudík; P Gabriel Steg; Pierre-Jean Touboul; Shinichiro Uchiyama; Éric Vicaut; Yongjun Wang; Lawrence K S Wong Journal: N Engl J Med Date: 2018-05-16 Impact factor: 91.245
Authors: Sarah E Vermeer; Monika Hollander; Ewoud J van Dijk; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: Stroke Date: 2003-04-10 Impact factor: 7.914
Authors: Eric E Smith; Martin O'Donnell; Gilles Dagenais; Scott A Lear; Andreas Wielgosz; Mukul Sharma; Paul Poirier; Grant Stotts; Sandra E Black; Stephen Strother; Michael D Noseworthy; Oscar Benavente; Jayesh Modi; Mayank Goyal; Saima Batool; Karla Sanchez; Vanessa Hill; Cheryl R McCreary; Richard Frayne; Shofiqul Islam; Jane DeJesus; Sumathy Rangarajan; Koon Teo; Salim Yusuf Journal: Ann Neurol Date: 2015-02 Impact factor: 10.422
Authors: Iain Turnbull; Robert Clarke; Neil Wright; Yu Guo; Christina Kartsonaki; Pei Pei; Alex Hacker; Canqing Yu; Simon Gilbert; Ling Yang; Jinyi Zhou; Sam Sansome; Jun Lv; Liming Li; Zhengming Chen; Yiping Chen Journal: Lancet Reg Health West Pac Date: 2022-03-05